Related Experiment Video

Updated: Nov 6, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.6K

Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity

Gloria J Hong1, Sandra S Stinnett1, Sharon F Freedman2

  • 1Department of Ophthalmology, Duke University, Durham, North Carolina.

Journal of AAPOS : the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus
|May 8, 2021
PubMed

Insights

Prophylactic laser treatment after initial anti-vascular endothelial growth factor (VEGF) therapy for retinopathy of prematurity (ROP) in infants reduced follow-up outpatient screening needs. This approach streamlines ROP management compared to current US guidelines.

Area of Science:

  • Ophthalmology
  • Neonatal Medicine
  • Pediatric Care

Background:

  • Managing retinopathy of prematurity (ROP) after anti-vascular endothelial growth factor (VEGF) treatment presents challenges.
  • Current United States (US) guidelines for ROP screening post-treatment are limited.

Purpose of the Study:

  • To evaluate the efficacy of prophylactic laser therapy in reducing outpatient ROP screening after initial bevacizumab treatment.
  • To compare this strategy with existing US ROP screening guidelines.

Main Methods:

  • Infants received initial bevacizumab treatment for ROP.
  • One group underwent prophylactic laser treatment before hospital discharge.
  • A control group followed current US ROP screening guidelines.

Main Results:

  • Prophylactic laser treatment significantly reduced the number of outpatient ROP screening examinations.
  • The duration of outpatient ROP screening was also decreased in the treated group.
  • This strategy offers a more efficient management pathway.

Conclusions:

  • Early prophylactic laser therapy can optimize ROP management post-bevacizumab.
  • This approach may decrease healthcare resource utilization for ROP follow-up.
  • Further research could refine ROP treatment protocols.

More Related Videos

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model09:56

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

Published on: January 21, 2018

9.5K
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.4K

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
788
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
919